newsfilter
← Latest News
GlobeNewswire·

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

--Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O Annual Congress--